Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | IGLV6-57 | P01721 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL516401 | 0.91 | CRHR1 (0.44) | CYP3A4LMNAESR1ALDH1A1TP53 | |
| SCHEMBL21065755 | 0.89 | CRHR1 (0.43) | CYP3A4LMNAESR1ALDH1A1TP53 | |
| Lithium Ion SCHEMBL19732781 | 0.89 | CRHR1 (0.43) | CYP3A4LMNAESR1ALDH1A1TP53 | |
| Hydrochloric Acid SCHEMBL11023677 | 0.89 | CRHR1 (0.43) | CYP3A4LMNAESR1ALDH1A1TP53 | |
| SCHEMBL25271025 | 0.88 | ALDH1A1 (0.45) | CYP3A4LMNAESR1ALDH1A1TP53 | |
| Methanesulfonamide SCHEMBL11382859 | 0.88 | ESR1 (0.47) | CYP3A4LMNAESR1ALDH1A1TP53 | |
| SCHEMBL29520654 | 0.87 | CYP3A4 (0.46) | CYP3A4LMNAALDH1A1TP53TSHR | |
| SCHEMBL328909 | 0.87 | CYP3A4 (0.46) | CYP3A4LMNAALDH1A1TP53TSHR | |
| SCHEMBL25270983 | 0.86 | ALDH1A1 (0.51) | CYP3A4LMNAESR1ALDH1A1TP53 | |
| SCHEMBL25230838 | 0.85 | ALDH1A1 (0.54) | CYP3A4LMNAALDH1A1TP53CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4446310-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | Asahi Kasei Kabushiki Kaisha (JP) | 2024-10-16 | — | — | EP | disclosed |
| CN-118382612-A | Method for producing blocked isocyanate compound and method for producing isocyanate compound | 旭化成株式会社 | 2024-07-23 | — | — | CN | disclosed |
| WO-2023106377-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | 旭化成株式会社 | 2023-06-15 | — | — | WO | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | CYP3A4 4589/4885LMNA 3509/4885ESR1 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.